Sean Lawman
Analyst
Morgan Stanley
Equibles does not estimate personal net worth.
About Sean Lawman
Sean Lawman is recorded as Analyst at Morgan Stanley. Sean Lawman has spoken on 3 earnings calls across 3 companies, most recently for Acadia Pharmaceuticals Inc on August 4, 2026. Those appearances were for Acadia Pharmaceuticals Inc (ACAD), Axsome Therapeutics, Inc. (AXSM) and Halozyme Therapeutics, Inc. (HALO). The companies whose calls Sean Lawman spoke on are classified in the Healthcare sector.
Sean Lawman on recent calls
“On debut stick, so clearly an acceleration there, but can you quantify how much of the recent demand reflects entirely new patients versus improved compliance, persistence or conversion from the oral formulation?”
“On the pipeline, ASX-12, the NDA narcolepsy, with the NDA submission plan for 12 and narcolepsy, how do you see differentiation versus existing therapies, particularly around cataplexy control and physician adoption?”
“Hope you're well and congratulations on a nice set of numbers. Was there, you know, the speed-down number today and you've upgraded guidance, but was there one particular area of strength that surprised you during the quarter and is driving the upgrade or is it more broad-based?”
Affiliation history
-
Morgan Stanley
Analyst
Transcript header (unverified)
Current